Takeshi Hatani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Takeshi Hatani has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Yoshinori Yoshida
Kyoto University
6 shared publications - Kenji Miki
Premium Research Institute for Human Metaverse Medicine (WPI‐PRIMe) The University of Osaka Osaka Japan
3 shared publications Shunsuke Funakoshi
Center for iPS Cell Research and Application, Kyoto University, Kyoto, 606-8507, Japan
3 shared publicationsAtsushi Kobori
Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Japan
2 shared publicationsIkue Takei
Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan
2 shared publicationsTakeshi Kimura
Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan
2 shared publications
Latest Publications
- Open Access
- 7 January 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (1) , eabj1793
A versatile and robust cell purification system with an RNA-only circuit composed of microRNA-responsive ON and OFF switches
MicroRNA-responsive ON and OFF switches provide a safe and time-saving method for purifying a wide range of cell types.
- 7 January 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (1) , eabj1793
Open AccessA versatile and robust cell purification system with an RNA-only circuit composed of microRNA-responsive ON and OFF switches
MicroRNA-responsive ON and OFF switches provide a safe and time-saving method for purifying a wide range of cell types.
- Open Access
- 21 June 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-15
ERRγ enhances cardiac maturation with T-tubule formation in human iPSC-derived cardiomyocytes
One of the earliest maturation steps in cardiomyocytes (CMs) is the sarcomere protein isoform switch between TNNI1 and TNNI3 (fetal and neonatal/adult troponin I). Here, we generate human induced pluripotent stem cells (hiPSCs) carrying a TNNI1EmGFP and TNNI3mCherry double reporter to monitor and isolate mature sub-populations during cardiac differentiation. Extensive drug screening identifies two compounds, an estrogen-related receptor gamma (ERRγ) agonist and an S-phase kinase-associated protein 2 inhibitor, that enhances cardiac maturation and a significant change to TNNI3 expression. Expression, morphological, functional, and molecular analyses indicate that hiPSC-CMs treated with the ERRγ agonist show a larger cell size, longer sarcomere length, the presence of transverse tubules, and enhanced metabolic function and contractile and electrical properties. Here, we show that ERRγ-treated hiPSC-CMs have a mature cellular property consistent with neonatal CMs and are useful for disease modeling and regenerative medicine.
- 21 June 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-15
Open AccessERRγ enhances cardiac maturation with T-tubule formation in human iPSC-derived cardiomyocytes
One of the earliest maturation steps in cardiomyocytes (CMs) is the sarcomere protein isoform switch between TNNI1 and TNNI3 (fetal and neonatal/adult troponin I). Here, we generate human induced pluripotent stem cells (hiPSCs) carrying a TNNI1EmGFP and TNNI3mCherry double reporter to monitor and isolate mature sub-populations during cardiac differentiation. Extensive drug screening identifies two compounds, an estrogen-related receptor gamma (ERRγ) agonist and an S-phase kinase-associated protein 2 inhibitor, that enhances cardiac maturation and a significant change to TNNI3 expression. Expression, morphological, functional, and molecular analyses indicate that hiPSC-CMs treated with the ERRγ agonist show a larger cell size, longer sarcomere length, the presence of transverse tubules, and enhanced metabolic function and contractile and electrical properties. Here, we show that ERRγ-treated hiPSC-CMs have a mature cellular property consistent with neonatal CMs and are useful for disease modeling and regenerative medicine.
- 1 November 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 505 (4) , 1251-1256
Nano-structural analysis of engrafted human induced pluripotent stem cell-derived cardiomyocytes in mouse hearts using a genetic-probe APEX2
- 1 November 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 505 (4) , 1251-1256
Nano-structural analysis of engrafted human induced pluripotent stem cell-derived cardiomyocytes in mouse hearts using a genetic-probe APEX2
- 10 July 2018
- Published by Springer Nature
- Vol. 1816, 79-92
Induction of Human Induced Pluripotent Stem Cells to Cardiomyocytes Using Embryoid Bodies
Specific cell lineages differentiated from human induced pluripotent stem cells (iPSCs) are promising sources for cell replacement therapy and are useful biomedical research tools for research on disease mechanisms and drug discovery. Among the different lineages, cardiac lineage has been one of the most efficiently differentiated through several established protocols. In this chapter, we describe our reproducible and highly efficient methodology for differentiating iPSCs into cardiomyocytes using embryoid bodies. We also describe methods to dissociate iPSC-derived cardiomyocytes and to evaluate iPSC-derived cardiomyocytes.
- 10 July 2018
- Published by Springer Nature
- Vol. 1816, 79-92
Induction of Human Induced Pluripotent Stem Cells to Cardiomyocytes Using Embryoid Bodies
Specific cell lineages differentiated from human induced pluripotent stem cells (iPSCs) are promising sources for cell replacement therapy and are useful biomedical research tools for research on disease mechanisms and drug discovery. Among the different lineages, cardiac lineage has been one of the most efficiently differentiated through several established protocols. In this chapter, we describe our reproducible and highly efficient methodology for differentiating iPSCs into cardiomyocytes using embryoid bodies. We also describe methods to dissociate iPSC-derived cardiomyocytes and to evaluate iPSC-derived cardiomyocytes.
- Open Access
- 1 January 2018
- Published by Elsevier in Cell Reports
- Vol. 22 (2) , 546-556
Identification of Cardiomyocyte-Fated Progenitors from Human-Induced Pluripotent Stem Cells Marked with CD82
- 1 January 2018
- Published by Elsevier in Cell Reports
- Vol. 22 (2) , 546-556
Open AccessIdentification of Cardiomyocyte-Fated Progenitors from Human-Induced Pluripotent Stem Cells Marked with CD82
- 1 September 2016
- Published by Elsevier in Journal of Cardiology
- Vol. 68 (3) , 241-247
Associations of residual left ventricular and left atrial remodeling with clinical outcomes in patients after aortic valve replacement for severe aortic stenosis
- 1 September 2016
- Published by Elsevier in Journal of Cardiology
- Vol. 68 (3) , 241-247
Associations of residual left ventricular and left atrial remodeling with clinical outcomes in patients after aortic valve replacement for severe aortic stenosis
- Open Access
- 8 January 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 19111
Enhanced engraftment, proliferation and therapeutic potential in heart using optimized human iPSC-derived cardiomyocytes
Human pluripotent stem cell-derived cardiomyocytes (CMs) are a promising tool for cardiac cell therapy. Although transplantation of induced pluripotent stem cell (iPSC)-derived CMs have been reported in several animal models, the treatment effect was limited, probably due to poor optimization of the injected cells. To optimize graft cells for cardiac reconstruction, we compared the engraftment efficiency of intramyocardially-injected undifferentiated-iPSCs, day4 mesodermal cells and day8, day20 and day30 purified iPSC-CMs after initial differentiation by tracing the engraftment ratio (ER) using in vivo bioluminescence imaging. This analysis revealed the ER of day20 CMs was significantly higher compared to other cells. Transplantation of day20 CMs into the infarcted hearts of immunodeficient mice showed good engraftment and echocardiography showed significant functional improvement by cell therapy. Moreover, the imaging signal and ratio of Ki67-positive CMs at 3 months post injection indicated engrafted CMs proliferated in the host heart. Although this graft growth reached a plateau at 3 months, histological analysis confirmed progressive maturation from 3 to 6 months. These results suggested that day20 CMs had very high engraftment, proliferation and therapeutic potential in host mouse hearts. They also demonstrate this model can be used to track the fate of transplanted cells over a long time.
- 8 January 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 19111
Open AccessEnhanced engraftment, proliferation and therapeutic potential in heart using optimized human iPSC-derived cardiomyocytes
Human pluripotent stem cell-derived cardiomyocytes (CMs) are a promising tool for cardiac cell therapy. Although transplantation of induced pluripotent stem cell (iPSC)-derived CMs have been reported in several animal models, the treatment effect was limited, probably due to poor optimization of the injected cells. To optimize graft cells for cardiac reconstruction, we compared the engraftment efficiency of intramyocardially-injected undifferentiated-iPSCs, day4 mesodermal cells and day8, day20 and day30 purified iPSC-CMs after initial differentiation by tracing the engraftment ratio (ER) using in vivo bioluminescence imaging. This analysis revealed the ER of day20 CMs was significantly higher compared to other cells. Transplantation of day20 CMs into the infarcted hearts of immunodeficient mice showed good engraftment and echocardiography showed significant functional improvement by cell therapy. Moreover, the imaging signal and ratio of Ki67-positive CMs at 3 months post injection indicated engrafted CMs proliferated in the host heart. Although this graft growth reached a plateau at 3 months, histological analysis confirmed progressive maturation from 3 to 6 months. These results suggested that day20 CMs had very high engraftment, proliferation and therapeutic potential in host mouse hearts. They also demonstrate this model can be used to track the fate of transplanted cells over a long time.
- 5 October 2012
- Published by Wiley in Respirology
- Vol. 18 (2) , 308-312
Septic pulmonary embolism due to periodontal disease
Background and objective: Septic pulmonary embolism due to periodontal disease (SPE‐PD) is rarely reported and little is known about its clinical features. The purpose of this study was to evaluate the clinical and radiological features, as well as outcome, in SPE‐PD.Methods: Patients' records were retrospectively reviewed and 12 patients with SPE‐PD were identified (10 men, mean age 60.5 years). The patients' demographic features, laboratory data, physical and radiological findings, and clinical outcomes were evaluated.Results: All but one patient were smokers. Eight of the 12 patients had comorbidities including hypertension (58%) and/or diabetes mellitus (17%). Prevalent symptoms were fever (67%) and chest pain (58%). Only two patients fulfilled the criteria of systemic inflammatory response syndrome; most of the subjects were not clinically severely ill. Blood cultures were negative in all cases. Contrast‐enhanced chest computed tomography (CT) showed multiple peripheral nodules in all 12 patients, wedge‐shaped peripheral lesions abutting on the pleura in 10 (83%) and a feeding‐vessel sign in 9 (75%). All patients recovered from their illness after antimicrobial therapy concomitant with tooth extraction or periodontal care. The median duration of antibiotic administration was 51 days.Conclusions: Most patients with SPE‐PD were not seriously ill. Contrast‐enhanced chest CT appeared to be useful to diagnose SPE‐PD.
- 5 October 2012
- Published by Wiley in Respirology
- Vol. 18 (2) , 308-312
Septic pulmonary embolism due to periodontal disease
Background and objective: Septic pulmonary embolism due to periodontal disease (SPE‐PD) is rarely reported and little is known about its clinical features. The purpose of this study was to evaluate the clinical and radiological features, as well as outcome, in SPE‐PD.Methods: Patients' records were retrospectively reviewed and 12 patients with SPE‐PD were identified (10 men, mean age 60.5 years). The patients' demographic features, laboratory data, physical and radiological findings, and clinical outcomes were evaluated.Results: All but one patient were smokers. Eight of the 12 patients had comorbidities including hypertension (58%) and/or diabetes mellitus (17%). Prevalent symptoms were fever (67%) and chest pain (58%). Only two patients fulfilled the criteria of systemic inflammatory response syndrome; most of the subjects were not clinically severely ill. Blood cultures were negative in all cases. Contrast‐enhanced chest computed tomography (CT) showed multiple peripheral nodules in all 12 patients, wedge‐shaped peripheral lesions abutting on the pleura in 10 (83%) and a feeding‐vessel sign in 9 (75%). All patients recovered from their illness after antimicrobial therapy concomitant with tooth extraction or periodontal care. The median duration of antibiotic administration was 51 days.Conclusions: Most patients with SPE‐PD were not seriously ill. Contrast‐enhanced chest CT appeared to be useful to diagnose SPE‐PD.
- Open Access
- 1 January 2011
- Published by Wiley in Journal of Arrhythmia
- Vol. 27 (Supplement) , OP07_5
Electrophysilogical Characteristics of Contiguous Pulmonary Veins in Patients with Atrial Fibrillation
- 1 January 2011
- Published by Wiley in Journal of Arrhythmia
- Vol. 27 (Supplement) , OP07_5
Open AccessElectrophysilogical Characteristics of Contiguous Pulmonary Veins in Patients with Atrial Fibrillation